Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07737717 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 4 entries
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 10 words
    • Site details revised at 3 of 3 sites
  2. Site details revised at 2 of 3 sitesv3
  3. Recruitment opened
    • Site details revised at 3 of 3 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
Trial Details
NCT Number NCT07737717
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov